Bayer to acquire Vividion Therapeutics for $2 billion

The German pharmaceutical company Bayer has announced to acquire Vividion Therapeutics for $2 billion.

After the acquisition, Bayer will own full rights to Vividion’s proprietary discovery platform, which comprises three integrated, synergistic components: an integrated data portal, a novel chemoproteomic screening technology, and a proprietary chemistry library.

The acquisition of Vividion will strengthen Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities. Under the terms of the agreement, Bayer will pay an upfront consideration of $1.5 billion and potential success-based milestone payments of up to $500 million.

The chemoproteomic screening platform of Vividion will be able to identify previously unknown binding pockets on well-validated protein targets by screening chemical probes against the entire human proteome to assess selectivity.

The Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division Stefan Oelrich said:

“This acquisition is a cornerstone of our strategy to fuel our pipeline with breakthrough innovation,” “Vividion’s technology is the most advanced in the industry, and it has demonstrated its ability to identify drug candidates that can target challenging proteins. Together with Bayer’s existing know-how, we will be able to develop first-in-class drug candidates, increasing the value of our pipeline. We want to provide innovative therapies for patients whose medical needs are not yet met by today’s treatment options.”

About Bayer

Bayer AG is one of the largest pharmaceutical companies in the world headquartered in Germany the company’s business include human and veterinary pharmaceuticals; agricultural chemicals, seeds and biotechnology products, and consumer healthcare products. Werner Baumann has been CEO since 2016.

About Vividion Therapeutics

Vividion Therapeutics, Inc. is a biotechnology company based in U.S.A, the company is focused in transforming the future of human health through the creation of selective small molecule medicines that drug traditionally inaccessible targets. Jeff Hatfield is the CEO of the company.